Orgenesis Stock Performance
| ORGS Stock | USD 0.60 0.45 300.00% |
Orgenesis holds a performance score of 23 on a scale of zero to a hundred. The company holds a Beta of -16.14, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Orgenesis are expected to decrease by larger amounts. On the other hand, during market turmoil, Orgenesis is expected to outperform it. Use Orgenesis sortino ratio and the relationship between the downside variance and period momentum indicator , to analyze future returns on Orgenesis.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Orgenesis are ranked lower than 23 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady technical and fundamental indicators, Orgenesis unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Orgenesis |
Orgenesis Relative Risk vs. Return Landscape
If you would invest 15.00 in Orgenesis on November 1, 2025 and sell it today you would earn a total of 45.00 from holding Orgenesis or generate 300.0% return on investment over 90 days. Orgenesis is currently generating 36.1962% in daily expected returns and assumes 122.9131% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Orgenesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orgenesis Target Price Odds to finish over Current Price
The tendency of Orgenesis Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.60 | 90 days | 0.60 | about 16.78 |
Based on a normal probability distribution, the odds of Orgenesis to move above the current price in 90 days from now is about 16.78 (This Orgenesis probability density function shows the probability of Orgenesis Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Orgenesis has a beta of -16.14. This indicates as returns on its benchmark rise, returns on holding Orgenesis are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Orgenesis is expected to outperform its benchmark. In addition to that Orgenesis has an alpha of 33.4711, implying that it can generate a 33.47 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Orgenesis Price Density |
| Price |
Predictive Modules for Orgenesis
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Orgenesis. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Orgenesis Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Orgenesis is not an exception. The market had few large corrections towards the Orgenesis' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Orgenesis, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Orgenesis within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 33.47 | |
β | Beta against Dow Jones | -16.14 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | 0.28 |
Orgenesis Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Orgenesis for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Orgenesis can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Orgenesis is way too risky over 90 days horizon | |
| Orgenesis has some characteristics of a very speculative penny stock | |
| Orgenesis appears to be risky and price may revert if volatility continues | |
| Orgenesis has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
Orgenesis Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Orgenesis Pink Sheet often depends not only on the future outlook of the current and potential Orgenesis' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Orgenesis' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29 M | |
| Cash And Short Term Investments | 837 K |
Orgenesis Fundamentals Growth
Orgenesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Orgenesis, and Orgenesis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orgenesis Pink Sheet performance.
| Return On Equity | -7.27 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (16.54) % | |||
| Current Valuation | 23.01 M | |||
| Shares Outstanding | 4.77 M | |||
| Price To Earning | 7.52 X | |||
| Price To Book | 1.26 X | |||
| Price To Sales | 15.21 X | |||
| Revenue | 530 K | |||
| EBITDA | (54.07 M) | |||
| Cash And Equivalents | 2.3 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 22.62 M | |||
| Debt To Equity | 0.64 % | |||
| Book Value Per Share | (3.30) X | |||
| Cash Flow From Operations | (14.84 M) | |||
| Earnings Per Share | (8.00) X | |||
| Total Asset | 14.55 M | |||
| Retained Earnings | (176.62 M) | |||
| Current Asset | 5.29 M | |||
| Current Liabilities | 14.92 M | |||
About Orgenesis Performance
Assessing Orgenesis' fundamental ratios provides investors with valuable insights into Orgenesis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Orgenesis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.Things to note about Orgenesis performance evaluation
Checking the ongoing alerts about Orgenesis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Orgenesis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orgenesis is way too risky over 90 days horizon | |
| Orgenesis has some characteristics of a very speculative penny stock | |
| Orgenesis appears to be risky and price may revert if volatility continues | |
| Orgenesis has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Orgenesis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orgenesis' stock is overvalued or undervalued compared to its peers.
- Examining Orgenesis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orgenesis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orgenesis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orgenesis' pink sheet. These opinions can provide insight into Orgenesis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.